Werewolf Therapeutics (HOWL) vs Veru (VERU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Veru (VERU) has outperformed Werewolf Therapeutics (HOWL) over the past year, losing 45.1% versus a loss of 51.6%. Over five years, HOWL leads with a -94.7% price change compared with -97.2% for VERU. Werewolf Therapeutics is the larger company by market cap ($47.6 million vs $42.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | VERU |
|---|---|---|
| Share price | $0.9799 | $2.47 |
| Market cap | $47.62M | $42.14M |
| 1-day change | +7.68% | +2.13% |
| YTD return | +43.53% | +13.08% |
| 1-year return | -51.60% | -45.12% |
| 5-year return | -94.67% | -97.18% |
| EPS (TTM) | $-0.73 | $-0.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.85 | $7.33 |
| 52-week low | $0.27 | $2.05 |
| Distance from 52-week high | -47.03% | -66.28% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +614.36% | +938.64% |
| Average volume | 6.80M | 242.06K |
| Shares outstanding | 48.60M | 17.05M |
| Employees | 39 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Veru
VERU stock →Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
HOWL vs VERU FAQ
Which is bigger, Werewolf Therapeutics or Veru?
Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $47.62M compared with $42.14M for Veru (VERU).
Which stock has performed better over the past year, HOWL or VERU?
VERU returned -45.12% over the past 12 months, compared with -51.60% for HOWL (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and Veru in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.